drugset
drugset / Trial / NCT03265288

Study of LAU-7b in the Treatment of Cystic Fibrosis in Adults

NCT03265288 ↗

Phase 2 Completed 166 enrolled Laurent Pharmaceuticals Inc. Cystic Fibrosis Foundation · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

An International Phase II, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of LAU-7b administered once-daily for 6 months for the treatment of CF.

Timeline

Start
2018-11-05
Primary completion
2021-09-15
Completion
2021-09-15

Drugs

EvaluationDrugModalityDoseRoute
Subject fenretinide Small molecule 300 mg Oral

Indications

cystic fibrosis